Lineage Cell Therapeutics LCTX
NYSE LCTX
$1.00 +0.02 (+2.03%)
As of: Oct 23, 2026 · 3:17 PM EDT

Lineage Cell Therapeutics (LCTX) Price to Earnings (2016 - 2019)

Updated

Lineage Cell Therapeutics' Price to Earnings came in at 5.30 for Q2 2019, up 54.0% from the prior quarter.

Analysis

Lineage Cell Therapeutics (LCTX) Price to Earnings (2016 - 2019) Analysis & Trends

For FY2016, Lineage Cell Therapeutics' Price to Earnings was 9.67.

  • The Q2 2019 figure represents the highest quarterly Price to Earnings since Q3 2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.05 Bn 1,098.63 Bn 19.71 Bn
2 Johnson & Johnson 635.34 Bn 555.20 Bn 17.30 Bn
3 AbbVie 504.85 Bn 477.96 Bn 12.70 Bn
4 Merck 358.37 Bn 312.75 Bn 12.21 Bn
5 Novartis Ag 290.48 Bn 254.47 Bn 11.24 Bn
6 Astrazeneca 265.13 Bn 238.81 Bn 12.86 Bn
7 Amgen 237.92 Bn 193.32 Bn 7.24 Bn
8 Gilead Sciences 194.98 Bn 169.17 Bn 6.22 Bn
9 Pfizer 171.45 Bn 118.10 Bn 10.94 Bn
10 Lineage Cell Therapeutics 250.75 Mn 50.27 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 5.30
Mar 31, 2019 3.44
Sep 30, 2017 6.13
Jun 30, 2017 4.80
Mar 31, 2017 3.35
Dec 31, 2016 9.68
Sep 30, 2016 13.90
API Access

Lineage Cell Therapeutics Price to Earnings API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-earnings&ticker=LCTX&period=max&api_key=YOUR_API_KEY